Intellect vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 39)
Intellect logo

Intellect

EmergingHealthcare

Mental Health Benefits

Intellect is a mental health platform providing employer-sponsored coaching, therapy, and wellbeing programs focused on the Asia-Pacific market. HQ: Singapore.

AI VisibilityBeta
Overall Score
D39
Category Rank
#421 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
43
Perplexity
43
Gemini
41

About

Intellect is a corporate mental health platform providing employers in Asia-Pacific access to mental health coaching, therapy, crisis support, and digital wellbeing programs for their employees. Founded in 2019 in Singapore by Theodoric Chew, the platform addresses the significant mental health challenges in Asian workplaces, where stigma around seeking mental health support has historically been higher than in Western markets but awareness is growing, particularly among younger workforce generations.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

39
Overall Score
81
#421
Category Rank
#17
81
AI Consensus
71
stable
Trend
stable
43
ChatGPT
80
43
Perplexity
75
41
Gemini
77
37
Claude
86
45
Grok
85

Key Details

Category
Mental Health Benefits
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Intellect
Mental Health Benefits

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.